Astellas, Cipla Must Pay Medicare for Drug Price Increases (1)

Drug products from Astellas Pharma Inc., India-based manufacturer Cipla Ltd., and others will have to pay Medicare back for certain prices that increased faster than inflation, the agency announced Wednesday.

The Centers for Medicare & Medicaid Services announced the list of 34 prescription drugs for which prices increased, and for which Part B beneficiary coinsurances may be lower between Oct. 1 and Dec. 31, 2023.

Select people who take these drugs can save between $1 and $618 per average dose, depending on their coverage, the CMS said. Astellas’ antifungal medication Cresemba and Cipla’s Zembri, an antibiotic used to ...